Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

Conclusion: 177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients.

Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Fernandez, R., Eppard, E., Lehnert, W., Jimenez-Franco, L. D., Soza-Ried, C., Ceballos, M., Ribbeck, J., Kluge, A., Rosch, F., Meckel, M., Zhernosekov, K., Kramer, V., Amaral, H. Tags: Clinical Investigations Source Type: research